Friday’s Top Performers: KBIO, RPRX, MCUR, HPJ, TCPI

Share

 

Friday was a short trading day, but that didn’t mean that there was;t an opportunity for many stocks to put in solid performances. The following stocks were some of Friday’s top performers:

KaloBios Pharmaceuticals Inc (KBIO)

The stock increased 30.79% or $8.2 on November 27, hitting $34.83. About 4.35M shares traded hands or 72.62% up from the average. KBIO has risen 6866.00% since April 27, 2015 and is uptrending. It has outperformed by 6867.36% the S&P500.

The institutional sentiment increased to 0.45 in Q2 2015. Its up 0.04, from 0.41 in 2015Q1. The ratio increased, as 8 funds sold all KaloBios Pharmaceuticals Inc shares owned while 3 reduced positions. 2 funds bought stakes while 3 increased positions. They now own 6.90 million shares or 22.14% less from 8.87 million shares in 2015Q1.

Opus Point Partners Management Llc holds 0.28% of its portfolio in KaloBios Pharmaceuticals Inc for 746,467 shares. Harbourvest Partners Llc owns 57,604 shares or 0.01% of their US portfolio. Moreover, Blair William & Co Il has 0% invested in the company for 53,635 shares. The California-based California Public Employees Retirement System has invested 0% in the stock. Citigroup Inc, a New York-based fund reported 2,745 shares.

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $109.82 million. The Firm is focused on the development of monoclonal antibody therapeutics for diseases that represent a burden to society and to patients and their families. It currently has negative earnings. The Firm operates through the development of pharmaceutical products segment.

Repros Therapeutics Inc (RPRX)

The stock increased 45.14% or $0.79 on November 27, hitting $2.54. About 7.54M shares traded hands or 646.53% up from the average. RPRX has declined 69.10% since April 27, 2015 and is downtrending. It has underperformed by 67.74% the S&P500.

Out of 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 0 rate it “Buy”, 1 “Sell”, while 2 “Hold”. This means 0 are positive. Repros Therapeutics was the topic in 4 analyst reports since August 20, 2015 according to StockzIntelligence Inc. Ladenburg Thalmann downgraded the stock on October 30 to “Neutral” rating. Brean Capital downgraded the shares of RPRX in a report on October 30 to “Hold” rating.

The institutional sentiment decreased to 0.74 in Q2 2015. Its down 0.46, from 1.2 in 2015Q1. The ratio is negative, as 23 funds sold all Repros Therapeutics Inc shares owned while 19 reduced positions. 16 funds bought stakes while 15 increased positions. They now own 14.48 million shares or 5.86% less from 15.38 million shares in 2015Q1.

Sarissa Capital Management Lp holds 1.86% of its portfolio in Repros Therapeutics Inc for 1.13 million shares. Destrier Capital Management Llc owns 329,030 shares or 0.57% of their US portfolio. Moreover, Rtw Investments Llc has 0.48% invested in the company for 229,364 shares. The New York-based General American Investors Co Inc has invested 0.35% in the stock. Baker Bros. Advisors Lp, a New York-based fund reported 1.96 million shares.

Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has a market cap of $42.56 million. The Company’s product candidates include Androxal and Proellex. It currently has negative earnings. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Macrocure Ltd (MCUR)

The stock increased 25.77% or $0.5 on November 27, hitting $2.44. About 7.00M shares traded hands or 410.95% up from the average. MCUR has declined 73.45% since April 27, 2015 and is downtrending. It has underperformed by 72.09% the S&P500.

Out of 5 analysts covering Macrocure (NASDAQ:MCUR), 0 rate it “Buy”, 0 “Sell”, while 5 “Hold”. This means 0 are positive. $20 is the highest target while $1 is the lowest. The $7.50 average target is 207.38% above today’s ($2.44) stock price. Macrocure was the topic in 9 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Zacks upgraded the stock on September 7 to “Hold” rating. Oppenheimer maintained the shares of MCUR in a report on August 20 with “Perform” rating.

MacroCure Ltd. is a biotechnology company. The company has a market cap of $32.42 million. The Firm is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers (VLUs). It currently has negative earnings. The Company’s product candidate, CureXcell, is an advanced wound care (AWC) therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process.

Highpower International Inc (HPJ)

The stock increased 24.14% or $0.56 on November 27, hitting $2.88. About 710,403 shares traded hands or 1189.51% up from the average. HPJ has declined 33.02% since April 27, 2015 and is downtrending. It has underperformed by 31.66% the S&P500.

The institutional sentiment decreased to 0.45 in Q2 2015. Its down 0.44, from 0.89 in 2015Q1. The ratio turned negative, as 5 funds sold all Highpower International Inc shares owned while 6 reduced positions. 2 funds bought stakes while 3 increased positions. They now own 1.33 million shares or 1.59% more from 1.31 million shares in 2015Q1.

Friedberg Investment Management holds 0.15% of its portfolio in Highpower International Inc for 9,860 shares. Rotella Capital Management Inc. owns 36,211 shares or 0.11% of their US portfolio. Moreover, Granite Investment Partners Llc has 0.08% invested in the company for 223,916 shares. The New York-based Spark Investment Management Llc has invested 0.05% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 285,045 shares.

Since June 15, 2015, the stock had 0 insider buys, and 1 insider sale for $106,464 net activity. Ma Wen Wei sold 24,000 shares worth $106,464.

Highpower International, Inc. is a company, through its subsidiaries, engaged in the manufacturing and trading of nickel metal hydride rechargeable batteries. The company has a market cap of $35.34 million. The Firm makes Nickel Metal Hydride batteries for both consumer and industrial applications. It has 7.79 P/E ratio. It is engaged in research and manufacturing of batteries; processing, marketing and research of battery materials, and research and production of advanced battery packs and systems.

TCP International Holdings Ltd (TCPI)

The stock increased 20.19% or $0.21 on November 27, hitting $1.25. About 755,959 shares traded hands or 317.56% up from the average. TCPI has declined 65.94% since April 27, 2015 and is downtrending. It has underperformed by 64.58% the S&P500.

The institutional sentiment increased to 0.86 in Q2 2015. Its up 0.23, from 0.63 in 2015Q1. The ratio increased, as 17 funds sold all TCP International Holdings Ltd shares owned while 11 reduced positions. 14 funds bought stakes while 10 increased positions. They now own 3.67 million shares or 6.21% less from 3.91 million shares in 2015Q1.

First Wilshire Securities Management Inc holds 0.72% of its portfolio in TCP International Holdings Ltd for 763,112 shares. Park West Asset Management Llc owns 682,044 shares or 0.27% of their US portfolio. Moreover, Ardsley Advisory Partners has 0.17% invested in the company for 316,174 shares. The Missouri-based Argent Capital Management Llc has invested 0.08% in the stock. Spark Investment Management Llc, a New York-based fund reported 68,400 shares.

TCP International Holdings Ltd. is a global well-known provider of energy efficient light-emitting diode (LED) and compact fluorescent lamp (CFL) lighting technologies. The company has a market cap of $29.55 million. The Firm designs, develops, makes and delivers energy efficient lamps, fixtures and Internet lighting control solutions. It has 9.34 P/E ratio. The Company’s portfolio of advanced LED and CFL lamps and fixtures enables it to address a range of applications required by its retail and commercial and industrial (C&I) customers.

COMMENTS: